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rancesco Pelliccia, MD, PHD,*‡ Cinzia Cianfrocca, MD,*‡ Giuseppe Rosano, MD, PHD,†
iuseppe Mercuro, MD,‡ Giulio Speciale, MD,* Vincenzo Pasceri, MD, PHD*
ome and Cagliari, Italy
bjectives We prospectively investigated the relationship of circulating endothelial progenitor cells at
ime of percutaneous coronary intervention to the subsequent development of in-stent restenosis or
rogression of coronary atherosclerosis.
ackground Endothelial progenitor cells provide an endogenous repair mechanism of the dysfunctional
ndothelium and therefore can play a pathogenic role in coronary atherosclerosis.
ethods We studied 155 consecutive stable angina patients (92 men, age 60  11 years). All patients had
ow cytometry the day before elective percutaneous coronary intervention in order to derive subpopulations
f endothelial progenitor cells. A control group of 20 normal subjects was considered for comparison.
esults At 8-month control angiography, 30 patients showed in-stent restenosis (restenosis group), 22
atients showed progression of coronary atherosclerosis (progression group), whereas the remaining 103
atients had neither in-stent restenosis nor progression of coronary atherosclerosis (stable group). Com-
arison of the 3 groups did not show any difference in risk factors, cardiac morphology and function,
xtension of coronary artery disease, and treatment. Absolute numbers of CD34/KDR/CD45– cells (i.e.,
rogenitors of endothelial lineage) measured in the restenosis group (1.41  0.64 cells/l) were signiﬁ-
antly higher than in the progression, stable, and control groups (1.03  0.53 cells/l, 1.07  0.46 cells/l,
nd 0.95  0.44 cells/l, respectively, p  0.05). Similarly, CD133/KDR/CD45– cells (i.e., progenitors of
ndothelial cells at an earlier stage) were signiﬁcantly higher in the restenosis (0.63  0.23 cells/l) com-
ared with progression, stable, and control groups (0.33  0.19 cells/l, 0.41  0.32 cells/l, and 0.36 
.15 cells/l, respectively, p  0.001). Also, numbers of CD14/CD45 cells (i.e., which have a role in
ngiogenesis via a paracrine effect) were signiﬁcantly different among the restenosis, progression, stable,
nd control groups (0.72  0.56 cells/l vs. 0.51  0.52 cells/l vs. 0.28  0.54 cells/l vs. 0.62  0.67
ells/l, respectively, p  0.05), whereas CD105/CD45–/CD34– cells (i.e., which have a receptor for
ransforming growth factor-beta) were similar among groups.
onclusions Patients with restenosis have higher numbers of subpopulations of endothelial progenitor
ells that incorporate into endothelial cells or play a role in arteriogenesis compared with controls and
atients with either progression of coronary atherosclerosis or stable disease. (J Am Coll Cardiol Intv
010;3:78–86) © 2010 by the American College of Cardiology Foundation
rom the *Department of Cardiovascular Diseases, San Filippo Neri Hospital, Rome, Italy; †Department of Medical Sciences,
stituto di Ricovero Cura a Carrettere Scientifico San Raffaele Pisana, Rome, Italy; and the ‡Department of Cardiovascular and
eurologic Diseases, University of Cagliari, Cagliari, Italy.anuscript received July 28, 2009; revised manuscript received October 13, 2009, accepted October 15, 2009.
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79esearch on stem cells has identified a population of bone
arrow–derived cells, called circulating endothelial progen-
tor cells (EPCs), that incorporate into sites of neovascular-
zation and are home to sites of endothelial denudation thus
ontributing to the maintenance of vascular homeostasis (1).
lthough extensive work has been conducted to verify if
PCs impairment plays a key role in coronary atherogenesis
2), it is still matter of debate if the extension and severity of
oronary artery disease are associated with reduced (3) or
ncreased (4) numbers of EPCs, as it remains unclear if
hese cells exert favorable or unfavorable effects at sites of
See page 87
ercutaneous coronary intervention (PCI) (5–7). One should
onsider, however, that most previous investigations have
een hampered by discordant definitions of EPCs and by
ifferent timing of EPCs sampling (8–10), thus determin-
ng much uncertainty on the role of EPCs in restenosis and
therosclerosis progression (10). Furthermore, development
f de novo lesions and post-PCI restenosis, which are
athophysiologically dissimilar (5), have not been examined
oncomitantly and serially over time.
Accordingly, the aim of this study was to carry out the
rst prospective assessment of the significance of subpopu-
ations of circulating EPCs in the subsequent occurrence of
estenosis or progression of coronary atherosclerosis after
CI. To this end, a pool of EPCs subtypes that are
uggested to play some role in atherosclerosis was measured
n a homogenous population of candidates to PCI. At
ariance with previous work, counts of EPCs were obtained
n baseline conditions before PCI in order to avoid the
onfounding effect that the procedure exerts on EPCs (8,9).
ethods
atient population. All patients who underwent an elective
nd successful single or multivessel PCI between July 1,
005, and June 30, 2006, were considered for the study.
nclusion criteria were presence of typical stable effort
ngina, positive stress test, and indication for PCI at
oronary angiography. Patients were suitable candidates
nly if complete revascularization of clinically important
tenoses were feasible by PCI, and if they underwent
-month control angiography. Exclusion criteria were:
) in-hospital death after PCI; 2) myocardial infarction
uring follow-up to exclude potential subacute stent throm-
osis (11); 3) unstable angina; 4) any increase in creatine
inase-myocardial band, troponin I, myoglobin, or liver
nzymes above upper normal limit before PCI; 5) left
entricular ejection fraction 30%; 6) renal failure with
reatinine 2 mg/dl; and 7) treatment with statins at
eferral. Also, patients were excluded if they had recent
urgery, immunological disease, immunosuppresion/ aepression, or organ transplantation. Patients with a history
f coronary artery bypass grafting and patients with ho-
ozygotic familial hypercholesterolemia were excluded, be-
ause, in general, such individuals have diffuse disease that
omplicates the angiographic measurement of nondilated
essel segments (12). Patients who had a drug-eluting stent
ere also excluded to avoid the effects that medications can
xert on intimal hyperplasia and endothelial healing (6,7).
inally, all patients agreed to perform an 8-month
ollow-up angiography and gave informed, written consent
o participate to the study. Thus, 160 patients (95 men, age
1  12 years) fulfilling the inclusion criteria could be
valuated for this study. Our institutional committee on
uman research approved the study.
ontrol group. We selected a cohort of healthy controls
omparable with the study population in terms of age, sex,
nd body mass index. Controls were referred for suspicion
f angina pectoris and underwent a complete diagnostic
ork-up, including echocardiography, stress test, and cor-
nary angiography. None of the controls had cardiac or
oncardiac diseases, such as malignancy, inflammatory dis-
ase, and kidney disease.
ercutaneous coronary angioplasty and adjunct drugs. Ac-
ording to our standard proto-
ol, all patients without contra-
ndications were pre-treated
ith aspirin 100 mg/day and
iclopidine 250 mg twice a day at
east 3 days before PCI or with
lopidogrel 300 mg at least 6 h
efore the procedure. After PCI,
he protocol-mandated antiplatelet therapy consisted of
spirin 100 mg/day indefinitely and ticlopidine 250 mg
wice a day or clopidogrel 75 mg/day for 1 month. Other
edications such as beta-blockers, statins, and angiotensin-
onverting enzyme inhibitors were given as appropriate.
lood samples and ﬂow cytometry. Peripheral blood sam-
les were taken after a 14-h overnight period the day before
CI. C-reactive protein was measured by a immunotur-
odimetric assay (Hitachi 912, Roche Diagnostic, Basel,
witzerland) with a sensitivity of 0.1 mg/l, with an intra-
nd interassay variation of 5%. The blood for stem cell
ssessment was kept at room temperature until analysis
ithin 2 h after drawing. Mononuclear cells were isolated
rom peripheral venous blood by Ficoll density gradient
entrifugation (Histopaque-1077, Sigma-Aldrich, Munich,
ermany) and prepared for fluorescent-activated cell sort-
ng. A panel of monoclonal antibodies was used: anti-CD45
HI30 clone, Becton Dickinson, San Jose, California),
nti-CD34 (8G12 clone, Becton Dickinson), anti-CD133
AC133 clone, Miltenyi Biotec, Auburn, California), anti-
D105 (endoglin, NI-3A1 clone, Ancell, Bayport, Minne-
ota), anti-CD14 (M5E2 clone, Becton Dickinson), and
Abbreviations
and Acronyms
EPC  endothelial progenitor
cell
PCI  percutaneous
coronary interventionllophycocyanin antivascular endothelial growth factor re-
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80eptor 2 (KDR, R&D Systems, Minneapolis, Minnesota).
onoclonal antibodies were conjugated with peridinin
hlorophyll protein, R-phycoerythrin, and fluorescein iso-
hiocyanate. The frequency of peripheral blood cells positive
or these reagents was determined by a scatter-fluorescence
ot-plot analysis stained with the different reagents. Fluo-
escence isotypes immunoglobulin G1- and G2a-matched
ntibodies were used as controls (Becton Dickinson). Cells
ere analyzed using sequential gating strategies that con-
ormed to International Society of Hematotherapy and
raft Engineering criteria to enumerate total number and
ubsets of circulating CD45– or CD45 cells (13). Also, we
ated CD34 and CD133 peripheral blood cells in the
ononuclear cell fraction and then examined the resulting
opulation for the dual expression of KDR.
Circulating EPCs were depicted by the lack of expression
f CD45 (i.e., a leukocyte/monocyte antigen), and by the
imultaneous expression of KDR (i.e., a marker of endothe-
ial lineage) and CD34 (i.e., a hematopoietic stem cell
arker that is also expressed on mature microvascular
ndothelial cells) (14) or CD133 (i.e., a more immature
ematopoietic stem cell marker that is absent on mature
ndothelial cells and monocytic cells (15). Accordingly, after
ating on the CD45 area, the resulting populations of cells
dentified by the dual expression of KDR and CD34
CD45–/CD34/KDR) or CD133 (CD45–/CD133/
DR) were evaluated (3,14). Also, analytical gates were
sed to enumerate subsets of circulating CD45–/CD34–
ells that expressed the antigen CD105 (16). Finally, circu-
ating CD45 leukocytes that expressed the monocytic
arker CD14 were assessed (1). These cells are derived
rom monocytes/macrophages and cannot be considered
arly EPCs (1). They are positive for both the leukocyte
ntigens CD45 and CD14 but are negative for the antigens
D34 and CD133 (10). Noteworthy, they have no prolif-
ration potential but play an important role in angiogenesis
nd arteriogenesis via a paracrine effect (17). Flow cytomet-
ic analysis was performed with a fluorescent-activated cell
orter Calibur laser flow cytometer (FACS Calibur, Becton
ickinson). Data were processed using the Cell-Quest
oftware (Becton Dickinson). The number of EPCs was
xpressed as the absolute number of cells per 1 l as whole
lood. All measurements were derived by 1 operator (G.M.)
ho was blind to the patients’ status.
To assess the reproducibility of EPCs measurements,
irculating EPCs were measured twice in the first 20
onsecutive patients from 2 separate blood samples drawn 1
ay apart before PCI.
uantitative coronary angiography. Analysis of coronary
ngiograms obtained before (baseline) and after PCI, as well
s at 8-month follow-up control was performed by the core
aboratory Ricerche Orientate alla Malattia Aterosclerotica
ROMA). The operators who performed the evaluation dere unaware of the study protocol, the patient character-
stics, and the stent type used. Digital angiograms were
nalyzed offline with the use of an automated edge-
etection system (Cardiovascular Medical System, MEDIS
maging Systems, Leiden, the Netherlands) (18). All mea-
urements were performed on cineangiograms recorded
fter intracoronary nitroglycerin administration (18–20).
ll visible lesions, including wall irregularities, were ana-
yzed on the angiograms. Multiple lesions within 1 coronary
rtery segment were considered distinct whenever separated
y a visually smooth arterial wall. The same single, worst-
iew projection was used at all time points. The contrast-
lled nontapered catheter tip was used for calibration, and
he reference diameter was measured by interpolation. At
aseline, all nondilated segments 2 mm in diameter with a
20% but 100% diameter stenosis were measured (12,18).
he angiographic measurements included reference vessel
iameter, minimal lumen diameter, diameter stenosis, and
esion length. For stented tracts, angiographic measurements
ere made both in the stent and in the stented segment
defined as the whole stented tract plus the 5-mm edges
roximal and distal to the stent) during diastole. Acute gain
as defined as the difference between minimal lumen diame-
ers at the end of PCI and at baseline. Late lumen loss was
alculated as the difference in minimal lumen diameter mea-
ured after PCI and at follow-up. Binary angiographic reste-
osis was defined as diameter stenosis 50% at follow-up
ngiography.
eﬁnitions. At baseline and follow-up coronary angio-
rams, quantitative coronary analysis allowed identification
f arteries with significant flow-limiting lesion as defined by
50% diameter stenosis of the lumen diameter. Proce-
ural success of PCI was defined as a decrease of stenosis
20% with a 30% residual narrowing. At follow-up
ngiograms, progression of coronary artery disease was
efined as new lesion or worsening of a previous lesion. A
ew lesion was considered to have developed when the
tenosis was only present at the 8-month coronary angiog-
aphy, as shown by a retrospective measurement of the
orresponding segment at baseline. Conversely, a lesion was
efined as progressive when a not significant lesion detected
t baseline angiography showed a change in minimal lumen
iameter 0.4 mm associated with a change in diameter
tenosis 20% (18–20). Stable coronary atherosclerosis was
efined when the minimal lumen diameter of any pre-
xisting lesion did not worsen by 0.4 mm or increased by
20% percent diameter stenosis and/or there was no
evelopment of a lesion reducing minimal lumen diameter
y 0.04 mm or determining a percent diameter stenosis
20% (16,18,19). Binary angiographic restenosis was de-
ned as diameter stenosis 50% in the in-segment area
including the stent area and 5-mm segments proximal and
istal to the stent edges) at follow-up angiography (21).
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81atients with both restenosis and progression of coronary
rtery disease were included in the restenosis group.
tatistical analysis. Data are presented as mean  SD for
ontinuous variables or frequency percentages for categorical
ariables. Kolmogorov-Smirnov testing was applied to as-
ess normality of distribution for continuous variables
CD34/CD45–, CD133/CD45–, CD34/KDR,
D133/KDR did not show normal distribution and
ere analyzed by nonparametric tests). Chi-square or Fisher
xact tests, when appropriate, were used to compare differ-
nces between categorical variables, respectively. Compari-
ons between multiple groups were performed by analysis of
ariance and multiple comparisons were done by t test with
onferroni correction in case of statistical significance. Not
ormally distributed continuous variables were compared by
ruskal-Wallis and Mann-Whitney U tests. Correlation
etween 2 variables was assessed with Pearson correlation
oefficient. Differences were considered statistically signifi-
ant if the p value was 0.05. Analyses were performed
ith the S-Plus statistical package (Mathsoft Inc., Seattle,
ashington). The authors had full access to the data and
ake responsibility for its integrity. All authors have read and
gree to the manuscript as written.
esults
atient population. After the index PCI, of the 160 patients
ho were prospectively included in the study, 1 patient died
hile in-hospital, 1 patient had ST-segment elevation
yocardial infarction, and 3 patients experienced non–ST-
egment elevation myocardial infarction. These 5 patients
ere excluded from further analysis as they could not
ndergo follow-up coronary angiography. Of note, no
ignificant difference was found in levels of EPCs between
hose patients with major adverse cardiac events and the
emaining patients, although the number of events was very
mall. In the other 155 patients (92 men, age 60  11
ears), 8-month control angiography showed significant
inary in-stent restenosis in 30 patients (restenosis group)
nd progression of coronary atherosclerosis in 1 segments
ith no evidence of in-stent restenosis in 22 patients
progression group). Three patients showed both restenosis
nd progression of coronary artery disease and were in-
luded in the restenosis group according to pre-specified
efinition. The remaining 103 patients had neither in-stent
estenosis nor progression of coronary atherosclerosis (stable
roup). The control group consisted of 20 normal subjects
13 men, mean age 61  9 years) with atypical chest pain
nd normal coronary angiography.
aseline clinical and angiographic features. The 3 groups of
atients were well matched with respect to age, sex, and
ardiovascular risk factors, and were similar with regard to
linical presentation (all patients had stable angina by study sesign), left ventricular function, renal function, and med-
cal therapy at time of PCI (Table 1). Comparison of
-reactive protein levels did not show any significant
ifference among the 3 groups of patients. No differences
ere noted among groups both in the PCI sites and in the
onintervened lesions, as coronary anatomy, number of
iseased vessels, number of significant coronary stenoses,
esion types, and stenosis characteristics (i.e., minimal lu-
en diameter, length, and severity) were similar among the
groups (Table 2). Specifically, there were no significant
ifferences in lesion severity or lesion location among the 3
roups.
rocedural characteristics and outcome. Procedural charac-
eristics (including total ischemia time), type of stents,
iameter and length of implanted stents were similar among
he 3 groups of patients (Table 2). There were no in-
ospital major complications (death or need for urgent
evascularization).
ollow-up quantitative coronary angiography. All patients
nderwent the 8-month follow-up coronary angiography.
indings of quantitative coronary angiography at sites of
revious PCI are shown in Table 3. A significant progres-
Table 1. Main Clinical Features in the 3 Groups of Patients
Restenosis
Group
(n  30)
Progression
Group
(n  22)
Stable
Group
(n  103) p Value
Men 18 (60%) 14 (64%) 60 (58%) NS
Women 12 (40%) 8 (36%) 33 (32%) NS
Age, yrs 62 10 60 8 59 9 NS
Risk factors
Diabetes mellitus 5 (17%) 3 (14%) 14 (14%) NS
Systemic hypertension 15 (50%) 12 (54%) 46 (45%) NS
Hypercholesterolemia 14 (45%) 11 (50%) 45 (44%) NS
Current smoker 7 (23%) 6 (27%) 28 (27%) NS
Family history of
coronary disease
7 (23%) 5 (23%) 27 (26%) NS
Previous MI 7 (23%) 4 (18%) 23 (22%) NS
Clinical ﬁndings
CCS anginal class I or II 18 (59%) 14 (63%) 70 (68%) NS
CCS anginal class III or IV 12 (41%) 8 (36%) 33 (32%) NS
LV ejection fraction, % 56 10 53 11 50 12 NS
Creatinine, mg/dl 1.0 0.3 1.1 0.4 1.2 0.5 NS
C-reactive protein, mg/l 1.87 1.77 1.63 1.65 1.71 1.59 NS
Drug therapy at discharge
Aspirin 28 (93%) 20 (91%) 94 (91%) NS
Beta-blockers 22 (73%) 15 (68%) 79 (77%) NS
ACE inhibitors 10 (33%) 8 (36%) 46 (45%) NS
Calcium antagonist 14 (47%) 9 (41%) 37 (36%) NS
Lipid-lowering drug 29 (97%) 22 (100%) 94 (91%) NS
Data are expressed as n (%) or mean SD.
ACE  angiotensin-converting enzyme; CCS  Canadian Cardiovascular Society; LV  left
ventricular; MImyocardial infarction.ion of coronary atherosclerosis in the non-PCI lesions was
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82ndicated by the development of significant coronary steno-
es, coupled with significantly lower minimal lumen diam-
ter and higher stenosis length and stenosis percent diam-
ter. In the progression group, new or progressive disease
ccurred in untreated vessels in 10 patients (46%), whereas
0 patients (46%) had progression in the same artery but in
separate segment (5 mm) from the original PCI, and 2
atients (9%) had progression in both treated and untreated
essels. Difference in in-stent luminal loss was minimal
etween the progression group and the stable group
Table 2. Quantitative Coronary Angiographic Findings at Baseline and
Procedural Characteristics in the 3 Groups of Patients
Restenosis
Group
(n  30)
Progression
Group
(n  22)
Stable
Group
(n  103) p Value
Nonsigniﬁcant coronary lesions
Number of nonsigniﬁcant
lesions/patient
4.1 2.9 3.6 3.1 3.9 3.7 NS
Patients with maximal
stenosis 20%
7 (23%) 6 (27%) 33 (32%) NS
Patients with maximal
stenosis 20%–50%
23 (77%) 16 (73%) 70 (68%) NS
Vessels with nonsigniﬁcant
stenoses
1-vessel 13 (43%) 10 (45%) 52 (51%) NS
2- or 3-vessel 17 (57%) 12 (55%) 51 (49%) NS
Left anterior descending artery 27 (90%) 18 (82%) 88 (85%) NS
Left circumﬂex artery 16 (53%) 11 (50%) 42 (41%) NS
Right coronary artery 12 (41%) 11 (50%) 56 (54%) NS
Reference vessel diameter, mm 3.03 0.59 2.99 0.41 2.98 0.45 NS
MLD, mm 1.95 0.29 1.94 0.37 1.96 0.35 NS
Diameter stenosis, % 35.6 9.8 35.1 11.2 34.2 10.5 NS
Lesion length, mm 16.9 8.8 14.3 6.9 16.1 7.1 NS
Signiﬁcant coronary lesions
Number of signiﬁcant stenoses/
patient
1.26 0.36 1.18 0.43 1.22 0.38 NS
Vessels with 1 stenosis 50%
1-vessel 19 (64%) 15 (68%) 70 (68%) NS
2- or 3-vessel 11 (37%) 7 (32%) 33 (32%) NS
Left anterior descending artery 18 (60%) 12 (55%) 66 (64%) NS
Left circumﬂex artery 12 (40%) 8 (36%) 32 (31%) NS
Right coronary artery 15 (50%) 10 (45%) 50 (48%) NS
MLD, mm 0.56 0.31 0.59 0.23 0.51 0.33 NS
Diameter stenosis, % 81.5 10.1 80.3 8.4 82.8 9.2 NS
Lesion length, mm 14.4 5.5 13.1 4.5 15.9 4.9 NS
PCI characteristics
Number of stents/patient 1.23 0.42 1.15 0.39 1.21 0.49 NS
Direct stenting 19 (63%) 15 (68%) 75 (73%) NS
Total stent length, mm 20.03 4.11 18.18 5.55 19.92 4.77 NS
Stent diameter, mm 3.13 0.39 3.05 0.41 3.19 0.44 NS
MLD post-PCI, mm 2.36 0.39 2.29 0.33 2.34 0.43 NS
Acute gain, mm 1.80 0.32 1.70 0.37 1.83 0.36 NS
Data are expressed as mean SD or n (%).
MLDminimal lumen diameter; PCI percutaneous coronary intervention.atients.lood samples and ﬂow cytometry. Statistical analysis re-
ealed a slight correlation (Pearson correlation coefficient
0.15) of borderline significance (p  0.051) between
D34/KDR/CD45– cells and CD133/KDR/
D45– cells. Of the 20 patients in whom reproducibility
f EPCs measurements were assessed at baseline, 14 were
ater included in the stable group, 3 in the restenosis
roup, and 3 in the progression group. Statistical analysis
isclosed a significant correlation between the 2 assess-
ents of CD34/KDR/CD45– cells (r  0.82, p 
.001), CD133/KDR/CD45– cells (r  0.92, p 
.001), CD105/CD45–/CD34 – cells (r  0.87,
 0.001), and CD14/CD45 cells (r  0.90, p 
Table 3. Quantitative Coronary Angiographic Findings at 8-Month
Follow-Up Control in the 3 Groups of Patients
Restenosis
Group
(n  30)
Progression
Group
(n  22)
Stable
Group
(n  103)
ANOVA
p Value
Nonstented segments
Patients with new stenoses
50%
3 22 0 —
Number of new stenoses 50% 3 28 0 —
New stenoses 50%/patient 0.10 1.27 0 —
Type of new stenoses 50%
De novo lesions/total lesions 1/3 10/28 0 —
Progression of lesions/total
lesions
2/3 18/28 0 —
Location of new stenoses 50%
Left anterior descending artery 2/3 12/28 0 —
Left circumﬂex artery 0 7/28 0 —
Right coronary artery 1/3 9/28 0 —
Reference vessel diameter, mm 3.12 0.69 3.02 0.47 3.01 0.47 NS
MLD, mm 1.91 0.44 0.55 0.24* 1.89 0.33 NS
Diameter stenosis, % 38.7 6.9 81.8 8.7* 37.2 9.5 NS
Lesion length, mm 13.8 5.7 15.1 4.9 16.9 6.1 NS
Stented segments
In-segment
MLD, mm 0.81 0.33† 2.03 0.39 2.07 0.41 0.001
Diameter stenosis, % 73.3 12.5† 32.1 9.8 30.5 10.1 0.001
Late lumen loss, mm 1.48 0.18† 0.21 0.12 0.25 0.11 0.001
In-stent MLD, mm 0.72 0.37† 2.18 0.49 2.14 0.39 0.001
Diameter stenosis, % 76.3 10.4† 27.8 7.1 28.9 8.5 0.001
Late lumen loss, mm 1.64 0.21† 0.11 0.09‡ 0.20 0.10 0.001
Degree of restenosis
Patients with restenosis 20% 0 (0%)† 16 (73%) 67 (65%) 0.0001
Patients with restenosis
20%–50%
0 (0%)† 6 (27%) 36 (35%) 0.0001
Patients with binary restenosis 30 (100%)† 0 (0%) 0 (0%) 0.0001
Data are expressed as n, mean  SD, or n (%). *p  0.05 for comparison between progression
group versus restenosis and stable groups. †p 0.05 for comparison between restenosis group
versus progression and stable groups. ‡p  0.05 for comparison between progression group
versus stable group.ANOVA analysis of variance; other abbreviations as in Table 2.
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83.001). Also, there were no differences between the first
nd the second assessments in mean SD and range of
D34/KDR/CD45– cells (1.49  0.54 cells/l vs.
.37  0.49 cells/l, 0.55 to 2.12 cells/l vs. 0.45 to 2.03
ells/l, respectively), CD133/KDR/CD45– cells
0.69  0.13 cells/l vs. 0.58  0.25 cells/l, 0.23 to
.98 cells/l vs. 0.27 to 0.91 cells/l, respectively),
D105/CD45–/CD34 – cells (1.61  0.59 cells/l vs.
.82  0.48 cells/l, 0.81 to 2.53 cells/l vs. 0.77 to 2.67
ells/l, respectively) and CD14/CD45 cells (0.59 
.42 cells/l vs. 0.79  0.48 cells/l, 0.22 to 1.23 cells/l
s. 0.18 to 1.11 cells/l), respectively.
ubpopulations of EPCs in the study groups. Stem cell
nalysis (Table 4) showed that patients and control groups
ad similar white cell count and mononuclear cells. The
bsolute numbers of CD34/KDR/CD45– cells mea-
ured in the restenosis group (1.41  0.64 cells/l) were
ignificantly (p  0.05) higher than in the progression,
table, and control groups (1.03  0.53 cells/l, 1.07 
.46 cells/l, and 0.95  0.44 cells/l, respectively). Simi-
arly, CD133/KDR/CD45– cells were significantly (p 
.001) higher in the restenosis (0.63 0.23 cells/l) compared
ith progression, stable, and control groups (0.33  0.19
ells/l, 0.41  0.32 cells/l, and 0.36  0.15 cells/l,
espectively). No significant difference in CD34 and
D133 subpopulations were found at comparison between
rogression or stable groups and control subjects. Also,
D105/CD45–/CD34– cells were similar between patients
nd control groups. Finally, numbers of CD14/CD45 cells
ere significantly (p 0.05) different at statistical comparison
mong groups, being significantly higher in patients with
estenosis than in stable patients (0.72  0.56 cells/l vs.
.28  0.54 cells/l, p  0.05) at statistical comparison
etween groups.
Table 4. Endothelial Progenitor Cells in the 3 Groups of Patients and Cont
Restenosis Group
(n  30)
Progress
(n 
White cells, 103/ml 6.75 1.21 6.95
Monocytes, 103/ml 0.54 0.27 0.56
CD34/CD45–, cells/l 3.55 2.33 3.67
CD133/CD45–, cells/l 2.41 2.07 2.91
CD34/KDR, cells/l 4.15 2.88 3.94
CD133/KDR, cells/l 2.87 2.18 2.44
CD34/KDR/CD45–, cells/l 1.41 0.64* 1.03
CD133/KDR/CD45–, cells/l 0.63 0.23* 0.33
CD105/CD45–/CD34–, cells/l 1.70 0.66 1.61
CD14/CD45, cells/l 0.72 0.56† 0.51
Data are expressed asmean SD. *p0.05 for comparisonbetween restenosis groupversus progr
‡p 0.05 for comparison between stable group versus control group.ANOVA analysis of variance.iscussion
he results of our study indicate that the subpopulations of
irculating stem/progenitor cells assessed at time of PCI are
ifferent in patients with subsequent restenosis as compared
ith patients who experience progression of coronary ath-
rosclerosis, those who have a stable disease, and control
ubjects. Interestingly, progression of coronary artery disease
as not associated with different levels of EPCs compared
ith patients with stable disease or even normal controls,
hereas patients with restenosis had higher levels of circu-
ating EPCs.
he relation of EPCs to atherosclerosis progression. The
evelopment of atherosclerotic lesions involves injury to
he endothelium, activation of platelets, adhesion of
eucocytes, and migration and proliferation of vascular
mooth muscle cells (12). For this reason, a role for EPCs
n atherogenesis has been advocated (2,22). The results of
ur study, conversely, demonstrate that there is no
ignificant association between the number of EPCs and
he subsequent development of de novo coronary stenoses
r progression of previously nonsignificant coronary le-
ions. Indeed, subpopulations of EPCs measured at time
f the index PCI did not differ between those patients
ho showed progressive disease and those who had
either progression of coronary atherosclerosis nor in-
tent restenosis. These findings differ from previous work
n the putative role of EPCs in atherogenesis, which have
escribed positive or negative relations of EPCs to
oronary artery disease progression (22), extension (3),
everity (23), and outcome (24). One should consider,
owever, that all previous clinical studies have been
ross-sectional, and none has investigated prospectively
he evolution of subclinical coronary atherosclerosis (11).
ur study, conversely, has permitted a serial assessment
bjects
oup Stable Group
(n  103)
Control Group
(n  20)
ANOVA
p Value
6.51 1.41 6.76 1.30 NS
0.53 0.27 0.59 0.21 NS
3.11 2.17 3.06 2.10 NS
2.14 1.98 2.28 1.87 NS
4.21 2.75 3.69 2.11 NS
2.38 1.96 2.33 1.84 NS
1.07 0.46 0.95 0.44 0.05
0.41 0.32 0.36 0.15 0.001
1.88 0.94 1.92 0.97 NS
0.28 0.54‡ 0.62 0.67 0.05
table, and control groups.†p0.05 for comparisonbetween restenosis groupversus stable group.rol Su
ion Gr
22)
0.91
0.21
3.15
2.12
2.15
2.29
0.53
0.19
0.72
0.52
ession, s
o
c
c
fi
a
E
a
a
w
a
p
t
c
l
T
h
w
i
n
T
p
h
c
P
d
b
p
n
b
s
o
n
i
c
C
c
d
f
s
t
p
c
E
a
e
u
c
p
u
r
s
h
E
t
(
s
u
C
t
t
P
c
t
C
n
o
a
c
c
d
t
o
C
q
a
i
r
S
o
a
E
l
w
s
d
w
B
p
r
d
o
o
m
f
o
p
e
h
p
r
e
r
C
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 3 , N O . 1 , 2 0 1 0
J A N U A R Y 2 0 1 0 : 7 8 – 8 6
Pelliccia et al.
Progenitor Cells and Atherosclerosis
84f the coronary atherosclerotic process with quantitative
oronary angiography (25). Apart from methodological
onsiderations, there are alternative explanations for our
ndings. Multiple studies have demonstrated an associ-
tion between the number and function of circulating
PCs and risk factors for coronary artery disease, such as
ge, physical training, smoking, diabetes, hypertension,
nd dyslipidemia (3), yet it cannot be determined
hether it is a mere association or a contributory factor in
therogenesis (4). Our results are in agreement with these
revious observations, as they question the hypothesis
hat circulating EPCs are causally related per se to
oronary atherogenesis.
Interestingly, we did not find any significant difference in
evels of EPCs between study population and normal controls.
his finding is at variance with previous investigations that
ave shown a difference between normal subjects and patients
ith coronary artery disease (10,23). The peculiar design and
nclusion criteria of our study might constitute possible expla-
ations for this discrepancy.
he relation of EPCs to in-stent restenosis. In our study,
atients who subsequently experienced in-stent restenosis had
igher levels of circulating CD34, CD133, and CD14 positive
ells with respect to the progression, stable, and control groups.
rogression of coronary atherosclerosis and in-stent restenosis
o not share common histological features, with the latter
eing caused only by exuberant smooth muscle cells hyper-
lasia without any significant lipid or foam cell compo-
ent (5). Indeed, there is the possibility that mobilized
one marrow progenitors differentiate into vascular
mooth muscle cells and therefore aggravate the severity
f restenosis (26).
The potential association between angiographic reste-
osis of bare-metal stents and EPCs has been described
n 2 previous studies that evaluated only the population of
ells that expressed the hematopoietic stem cell marker
D34. Schober et al. (6) reported that post-PCI CD34
ell counts were increased in patients with restenosis but
ecreased in those without restenosis, and Inoue et al. (7)
ound that the increase in CD34 cells after bare-metal
tenting was more striking in patients with restenosis
han without restenosis. Our findings confirm and ex-
and these observations and demonstrate that the out-
ome of PCI is associated with the baseline pattern of
PCs, as we found higher levels of circulating CD34
nd CD133 cells in those patients who subsequently
xperienced restenosis. The importance of our findings is
nderscored by the minimal overlap of numbers of EPCs
ounts between the restenosis group and the stable,
rogression, and control groups. Unfortunately, we were
nable to establish if the increased number of EPCs
esulted in their homing and migration into coronary
tents. One should consider, however, that previous
uman and animal models have described engraftment of sPCs in in-stent neointima. Specifically, previous inves-
igators have noted unexpectedly high expression of c-kit
27) and CD34 (28) in tissue from human atherectomy
pecimens of in-stent neointima. Thus, one might spec-
late that an abnormal engraftment of CD34 and
D133 EPCs causing excessive intima prolifera-
ion and in-stent restenosis may occur particularly in
hose patients who have greater levels of EPCs at time of
CI.
Our results indicate also a link between stem/progenitor
ells that promote the development of new blood vessels and
he damage healing after angioplasty (29). Indeed, CD14/
D45 monocyte-derived cells have the ability to enhance
eovascularization in experimental models with the release
f growth factors, such as vascular endothelial growth factor,
s recently shown by Sieveking et al. (17). These so-called
irculating angiogenic cells were found to be positively
orrelated with the presence and severity of coronary artery
isease by Guven et al. (10), who therefore hypothesized
hat these cells play a role in the progression or stabilization
f vascular disease. Our finding that baseline numbers of
D14/CD45 cells were higher in patients with subse-
uent restenosis suggests also that excessive circulating
ngiogenic cells may contribute to the pathogenesis of
n-stent restenosis, perhaps because they trigger redundant
e-endothelialization.
tudy limitations. For the purpose of this study, we included
nly candidates to PCI, and therefore we are unable to draw
definite conclusion on the general relationship between
PCs and coronary artery disease. A limitation of this study
ies in the fact that the numbers of patients in each group
ere relatively small. Also, differences in the number of each
ubtype of EPCs were relatively narrow, though significant
ifferences between restenosis and no-restenosis groups
ere found. However, use of strict statistical analysis with
onferroni correction and the evidence that 3 EPC sub-
opulations showed a similar behavior (all increased in the
estenosis group) make very unlikely that our findings were
ue to chance.
A major limit of our study is the lack of functional studies
f EPCs. Unfortunately, isolation of significant quantities
f cells for functional assays could not be possible in the
ajority of our patients and therefore we could not perform
unctional studies as previously done (4). Also, a limitation
f flow cytometric analysis was that we did not assess what
ercentage of CD133 cells were also CD34. We did not
stablish if the increased number of EPCs resulted in their
oming and migration into coronary arteries. It is not
ossible to know if mobilized bone marrow progenitors
eally differentiate into vascular smooth muscle cells or
ndothelial cells within coronary segments. Also, we cannot
ule out the possibility that the increase in CD34 and
D133 cells was caused by tissue ischemia, which can pere contribute to raise vascular endothelial growth factor
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85evels and mobilize cells into peripheral blood (4). However,
t is unlikely that myocardial ischemia affected our results
ecause all patients had flow-limiting coronary stenoses before
evascularization. Although we used well-established, quanti-
ative angiographic analytic methods, angiography is known to
nderestimate the extent of coronary atherosclerosis, especially
n comparison to intravascular ultrasonography. We were
nable to acquire routinely intravascular ultrasound data, and
herefore we cannot exclude a role for negative vascular
emodeling at the non-PCI sites of native coronary atheroscle-
osis. However, it has been recently demonstrated that quan-
itative coronary angiography and intravascular ultrasound
easures of lumen size correlate very well (25). We did not
erform a multivariate analysis for confounders of restenosis
ecause of the relatively small sample size of patients with
n-stent restenosis. Although pharmacologic agents (in partic-
lar statins) may affect numbers of EPCs (30), it is unlikely
hat differences in EPCs levels among groups were caused
y drug treatment, as medications were similar in the 3
roups of patients and those patients who were on statins
t referral were not included in the study. The short-term
ngiographic follow-up (8 months) may have limited the
bility to detect a role for EPCs in long-term evolution of
oronary atherosclerosis.
onclusions
ur study indicates that patients with restenosis have higher
umbers of subpopulations of EPCs that incorporate into
ndothelial cells or play a role in arteriogenesis compared
ith controls and patients with either progression of coro-
ary atherosclerosis or stable disease. Therefore, further
tudies are needed to identify the mechanism or the cause-
ffect relationship of EPCs in restenosis.
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